BLUE Stock UPDATES Bluebird Bio Inc (BLUE) 38.44 09/07/2014
Post# of 273334
Posted On: 09/07/2014 1:42:33 PM
Bluebird Bio Inc (BLUE) 38.44 $BLUE
Insider Trading Alert - BLUE, BHI And HCP Traded By Insiders
at The Street - Thu Sep 04, 10:00AM CDT
Stocks with insider trader activity include BLUE, BHI and HCP
bluebird bio to Present at Morgan Stanley Global Health Care Conference
Business Wire - Tue Sep 02, 4:30PM CDT
bluebird bio, Inc. (Nasdaq: BLUE) announces that management will present at the Morgan Stanley Global Healthcare Conference on Wednesday, September 10, 2014 at 2.30 PM ( EDT) at the Grand Hyatt New York Hotel, New York, NY.
Bluebird Bio (BLUE) Stock: Weak On High Volume Today
at The Street - Tue Sep 02, 9:01AM CDT
Trade-Ideas LLC identified bluebird bio (BLUE) as a weak on high relative volume candidate
Critical Alerts For bluebird bio Inc., United Therapeutics Corporation, Mattel Inc, Ulta Salon Cosmetics & Fragrance Inc. and Applied Materials Inc. Released By InvestorsObserver
PR Newswire - Tue Sep 02, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for BLUE, UTHR, MAT, ULTA and AMAT.
5 Stocks Triggering Big Breakout Trades
at The Street - Mon Aug 18, 10:12AM CDT
These stocks look poised to break out and trade higher from current levels.
bluebird bio Reports Fiscal Second Quarter 2014 Financial Results
Business Wire - Tue Aug 12, 4:00PM CDT
bluebird bio, Inc. (Nasdaq: BLUE), a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic and orphan diseases, today reported financial results and operational highlights for the quarter ended June 30, 2014.
bluebird bio to Present at Two Upcoming Health Care Conferences
Business Wire - Tue Aug 05, 3:06PM CDT
bluebird bio, Inc. (Nasdaq: BLUE) announces that management will present at the Wedbush Life Science Conference on Wednesday, August 13, 2014 at 12.40 PM (EDT) at the Parker Meridian Hotel, New York, NY. Management will also present at the Canaccord Genuity Growth Conference on Thursday, August 14, 2014 at 2:00 PM (EDT) at the InterContinental Hotel, Boston, MA.
5 Stocks Ready for Breakouts
at The Street - Mon Aug 04, 9:14AM CDT
These stocks are within range of triggering breakout trades.
Acquisition Agreements, Rejected Acquisition Tender Offers, Appointment, and Technical Updates - Research Reports on Pfizer, Gentiva, bluebird bio, Agios and AcelRx
PR Newswire - Wed Jul 23, 7:30AM CDT
Today, Analysts Review released its research reports regarding Pfizer Inc. (NYSE: PFE), Gentiva Health Services Inc. (NASDAQ: GTIV), bluebird bio, Inc. (NASDAQ: BLUE), Agios Pharmaceuticals, Inc. (NASDAQ: AGIO) and AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/5013-100free.
3 Biotech Stocks Breaking Out on Big Volume
at The Street - Mon Jul 21, 8:10AM CDT
These biotech stocks rising on unusual volume are within range of triggering breakout trades.
bluebird bio, Inc. (BLUE) in Focus: Stock Surges 10.24% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Jul 21, 7:44AM CDT
bluebird bio, Inc. (BLUE) was a big mover last session, as the company saw its shares surge over 10% on the day.
Buying Bluebird's Blockbuster Potential at a Discount
at The Street - Thu Jul 17, 9:33AM CDT
It's not often an investor gets the opportunity to buy a biotech stock with two blockbuster indications in the pipeline and major catalysts only months away at such a discount.
bluebird bio Appoints Mark Vachon to its Board of Directors
Business Wire - Wed Jul 16, 3:05PM CDT
bluebird bio (Nasdaq: BLUE), a clinical-stage biotechnology company focused on transforming the lives of patients with severe genetic and orphan diseases using gene therapy, today announced that Mark Vachon has joined the company's board of directors.
Grading Sobek's Mid-Year Biotech Stock Predictions
at The Street - Wed Jul 09, 9:14AM CDT
The year is halfway over, so it's a good time to look back and give mid-term grades on my fearless 2014 predictions.
bluebird bio Announces Pricing of Public Offering of Common Stock
Business Wire - Tue Jul 08, 5:58PM CDT
bluebird bio, Inc. (Nasdaq: BLUE), a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic and orphan diseases, today announced the pricing of an underwritten public offering of 3,000,000 shares of its common stock at a public offering price of $34.00 per share, before underwriting discounts. In addition, bluebird bio has granted the underwriters a 30-day option to purchase from it up to an additional 450,000 shares of common stock.
Today's 3 Most Volatile Biotech Stocks
Todd Campbell, The Motley Fool - Motley Fool - Tue Jul 08, 4:05PM CDT
Biotechnology stocks are never short on volatility and today was no different as markets turned lower and biotech stocks were particularly hard hit. The Nasdaq Biotechnology Index ETF dropped more than 2% as investors embraced safety and avoided...
Why bluebird bio Inc. Stock Faltered
Sean Williams, The Motley Fool - Motley Fool - Tue Jul 08, 1:17PM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of bluebird bio , a clinical-stage...
bluebird bio Announces Proposed Public Offering of Common Stock
Business Wire - Mon Jul 07, 3:02PM CDT
bluebird bio, Inc. (Nasdaq: BLUE), a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic and orphan diseases, today announced that it has commenced an underwritten public offering of $100 million of its common stock. bluebird bio also intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of common stock offered in the public offering.
Positive Study Results, Patent Grants, Acquisitions, Patient Enrollment, and Earnings Schedule - Analyst Notes on Synageva, OPKO, bluebird bio, BioDelivery Sciences and Haemonetics
PR Newswire - Thu Jul 03, 4:10AM CDT
Today, Analysts Review released its analysts' notes regarding Synageva BioPharma Corp. (NASDAQ: GEVA), Opko Health Inc. (NYSE: OPK), bluebird bio Inc. (NASDAQ: BLUE), BioDelivery Sciences International, Inc. (NASDAQ: BDSI) and Haemonetics Corporation (NYSE: HAE). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/4405-100free.
bluebird bio Acquires Precision Genome Engineering, a Privately Held Gene-Editing Company
Business Wire - Mon Jun 30, 3:05PM CDT
bluebird bio, Inc. (Nasdaq: BLUE), a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic and orphan diseases, today announced the acquisition of Precision Genome Engineering, Inc., or Pregenen, a privately held biotechnology company headquartered in Seattle, Washington. Pregenen is a leader in the development of gene editing and cell signaling technologies with a broad range of potential therapeutic applications.
Insider Trading Alert - BLUE, BHI And HCP Traded By Insiders
at The Street - Thu Sep 04, 10:00AM CDT
Stocks with insider trader activity include BLUE, BHI and HCP
bluebird bio to Present at Morgan Stanley Global Health Care Conference
Business Wire - Tue Sep 02, 4:30PM CDT
bluebird bio, Inc. (Nasdaq: BLUE) announces that management will present at the Morgan Stanley Global Healthcare Conference on Wednesday, September 10, 2014 at 2.30 PM ( EDT) at the Grand Hyatt New York Hotel, New York, NY.
Bluebird Bio (BLUE) Stock: Weak On High Volume Today
at The Street - Tue Sep 02, 9:01AM CDT
Trade-Ideas LLC identified bluebird bio (BLUE) as a weak on high relative volume candidate
Critical Alerts For bluebird bio Inc., United Therapeutics Corporation, Mattel Inc, Ulta Salon Cosmetics & Fragrance Inc. and Applied Materials Inc. Released By InvestorsObserver
PR Newswire - Tue Sep 02, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for BLUE, UTHR, MAT, ULTA and AMAT.
5 Stocks Triggering Big Breakout Trades
at The Street - Mon Aug 18, 10:12AM CDT
These stocks look poised to break out and trade higher from current levels.
bluebird bio Reports Fiscal Second Quarter 2014 Financial Results
Business Wire - Tue Aug 12, 4:00PM CDT
bluebird bio, Inc. (Nasdaq: BLUE), a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic and orphan diseases, today reported financial results and operational highlights for the quarter ended June 30, 2014.
bluebird bio to Present at Two Upcoming Health Care Conferences
Business Wire - Tue Aug 05, 3:06PM CDT
bluebird bio, Inc. (Nasdaq: BLUE) announces that management will present at the Wedbush Life Science Conference on Wednesday, August 13, 2014 at 12.40 PM (EDT) at the Parker Meridian Hotel, New York, NY. Management will also present at the Canaccord Genuity Growth Conference on Thursday, August 14, 2014 at 2:00 PM (EDT) at the InterContinental Hotel, Boston, MA.
5 Stocks Ready for Breakouts
at The Street - Mon Aug 04, 9:14AM CDT
These stocks are within range of triggering breakout trades.
Acquisition Agreements, Rejected Acquisition Tender Offers, Appointment, and Technical Updates - Research Reports on Pfizer, Gentiva, bluebird bio, Agios and AcelRx
PR Newswire - Wed Jul 23, 7:30AM CDT
Today, Analysts Review released its research reports regarding Pfizer Inc. (NYSE: PFE), Gentiva Health Services Inc. (NASDAQ: GTIV), bluebird bio, Inc. (NASDAQ: BLUE), Agios Pharmaceuticals, Inc. (NASDAQ: AGIO) and AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/5013-100free.
3 Biotech Stocks Breaking Out on Big Volume
at The Street - Mon Jul 21, 8:10AM CDT
These biotech stocks rising on unusual volume are within range of triggering breakout trades.
bluebird bio, Inc. (BLUE) in Focus: Stock Surges 10.24% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Jul 21, 7:44AM CDT
bluebird bio, Inc. (BLUE) was a big mover last session, as the company saw its shares surge over 10% on the day.
Buying Bluebird's Blockbuster Potential at a Discount
at The Street - Thu Jul 17, 9:33AM CDT
It's not often an investor gets the opportunity to buy a biotech stock with two blockbuster indications in the pipeline and major catalysts only months away at such a discount.
bluebird bio Appoints Mark Vachon to its Board of Directors
Business Wire - Wed Jul 16, 3:05PM CDT
bluebird bio (Nasdaq: BLUE), a clinical-stage biotechnology company focused on transforming the lives of patients with severe genetic and orphan diseases using gene therapy, today announced that Mark Vachon has joined the company's board of directors.
Grading Sobek's Mid-Year Biotech Stock Predictions
at The Street - Wed Jul 09, 9:14AM CDT
The year is halfway over, so it's a good time to look back and give mid-term grades on my fearless 2014 predictions.
bluebird bio Announces Pricing of Public Offering of Common Stock
Business Wire - Tue Jul 08, 5:58PM CDT
bluebird bio, Inc. (Nasdaq: BLUE), a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic and orphan diseases, today announced the pricing of an underwritten public offering of 3,000,000 shares of its common stock at a public offering price of $34.00 per share, before underwriting discounts. In addition, bluebird bio has granted the underwriters a 30-day option to purchase from it up to an additional 450,000 shares of common stock.
Today's 3 Most Volatile Biotech Stocks
Todd Campbell, The Motley Fool - Motley Fool - Tue Jul 08, 4:05PM CDT
Biotechnology stocks are never short on volatility and today was no different as markets turned lower and biotech stocks were particularly hard hit. The Nasdaq Biotechnology Index ETF dropped more than 2% as investors embraced safety and avoided...
Why bluebird bio Inc. Stock Faltered
Sean Williams, The Motley Fool - Motley Fool - Tue Jul 08, 1:17PM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of bluebird bio , a clinical-stage...
bluebird bio Announces Proposed Public Offering of Common Stock
Business Wire - Mon Jul 07, 3:02PM CDT
bluebird bio, Inc. (Nasdaq: BLUE), a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic and orphan diseases, today announced that it has commenced an underwritten public offering of $100 million of its common stock. bluebird bio also intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of common stock offered in the public offering.
Positive Study Results, Patent Grants, Acquisitions, Patient Enrollment, and Earnings Schedule - Analyst Notes on Synageva, OPKO, bluebird bio, BioDelivery Sciences and Haemonetics
PR Newswire - Thu Jul 03, 4:10AM CDT
Today, Analysts Review released its analysts' notes regarding Synageva BioPharma Corp. (NASDAQ: GEVA), Opko Health Inc. (NYSE: OPK), bluebird bio Inc. (NASDAQ: BLUE), BioDelivery Sciences International, Inc. (NASDAQ: BDSI) and Haemonetics Corporation (NYSE: HAE). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/4405-100free.
bluebird bio Acquires Precision Genome Engineering, a Privately Held Gene-Editing Company
Business Wire - Mon Jun 30, 3:05PM CDT
bluebird bio, Inc. (Nasdaq: BLUE), a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic and orphan diseases, today announced the acquisition of Precision Genome Engineering, Inc., or Pregenen, a privately held biotechnology company headquartered in Seattle, Washington. Pregenen is a leader in the development of gene editing and cell signaling technologies with a broad range of potential therapeutic applications.
(0)
(0)